June 2009
Worldwide Biotech;Jun2009, Vol. 21 Issue 6, p3
Trade Publication
The article reports that Bayer Healthcare AG and Regeneron Pharmaceuticals have extended their development program for the investigational drug, vascular endothelial growth factor (VEGF) Trap-Eye, in June 2009. The phase three program will evaluate the efficiency and safety of the investigational drug in the treatment of central retinal vein occlusion (CRVO). A brief information on CRVO is offered. The program will also conduct an investigation into the efficiency of the drug in patients with neovascular form of age-related macular degeneration (wet AMD)


Related Articles

  • VEGF Trap Results Show VA Improvment in DME Patients.  // Review of Ophthalmology;Mar2010, Vol. 17 Issue 3, p4 

    The article reports on the study conducted by Regeneron Pharmaceuticals Inc. and Bayer HealthCare AG that determines the efficacy of Vascular Endothelial Growth Factor (VEGF) Trap-Eye in the treatment for patients with diabetic macular edema. It states that the result of the study was met in...

  • Regeneron, Bayer Expanding Phase III VEGF Trap-Eye Trials.  // BioWorld Today;5/1/2009, Vol. 20 Issue 83, p2 

    The article reports on the plan of Regeneron Pharmaceuticals Inc. and Bayer HealthCare AG to include central retinal vein occlusion (CRVO) in their global development program for Vascular Endothelial Growth Factor (VEGF) Trap-Eye. A Phase III program testing the efficacy and safety of VEGF...

  • Regeneron and Bayer complete enrollment in two Phase III AMD trials.  // PharmaWatch: Biotechnology;Nov2009, Vol. 8 Issue 11, p12 

    The article reports that biopharmaceutical company Regeneron Pharmaceuticals Inc. and Bayer HealthCare AG have finished patient enrollment in two Phase III clinical trials assessing vascular endothelial growth factor (VEGF) Trap-Eye in age-related macular degeneration (AMD) treatment. In each...

  • VEGF Trap undergoing global development.  // Ophthalmology Times;12/1/2006, Vol. 31 Issue 23, p4 

    The article reports on the collaboration between Bayer Healthcare and Regeneron Pharmaceuticals Inc. in the U.S. The partnership was designed for the worldwide commercialized development of the vascular endothelial growth factor (VEGF) Trap for the potential treatment of the neovascular form of...

  • Next-generation AMD drugs to wed blockbusters. Ratner, Mark // Nature Biotechnology;Aug2014, Vol. 32 Issue 8, p701 

    The article offers information on trends related to drugs for treating age-related macular degeneration (AMD) and other eye diseases as of August 2014. The topics discussed include the side effects of vascular endothelial growth factor (VEGF) inhibitors including Lucentis and Eylea, drug targets...

  • Search for optimal anti-VEGF dosing strategy in AMD continues.  // Ocular Surgery News;11/10/2009, Vol. 27 Issue 21, p19 

    The article focuses on the continued search for optimal anti-vascular endothelial growth factors (VEGF) dosing strategy in age-related macular degeneration (AMD). According to Doctor Philip J. Rosenfeld, future treatment decisions could be influenced by head-to-head trials of Lucentis and...

  • Vascular Endothelial Growth Factor: A New Frontier in Macular Degeneration. Gerson, Jeffry // Review of Optometry;11/15/2006 Part 2 of 2, Vol. 143, p4 

    The article provides an overview of the anti-vascular endothelial growth factor therapies that aid in the treatment of patients with age-related macular degeneration in the U.S. Drug treatments approved by the U.S. Food and Drug Administration, which have been discovered to be efficacious, are...

  • Retina. Dunbar, Mark T. // Review of Optometry;5/15/2012, Vol. 149 Issue 5, p54 

    The article discusses the effects of retinal anatomy on age-related macular degeneration (AMD) treatment trials (CATT) outcomes. The author examines the implications of genetic predisposition to AMD based on CATT data. He offers comments on the new findings on anti- vascular endothelial growth...

  • Frequency of anti-VEGF treatment trends toward extended intervals. Morgan, Daniel R.; Nale, Patricia; Stiglich, Joan-Marie // Primary Care Optometry News;Mar2014, Vol. 19 Issue 3, p16 

    The article reports on the extension of the intervals for treating patients with age-related macular degeneration with anti-vascular endothelial growth factor (VEGF) injections discussed by Doctor Elias Reichel at the Hawaiian Eye 2014 meeting held in Koloa, Hawaii on January 18-24.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics